The fact that 99% of trial participants chose to continue in the open-label extension speaks volumes about the treatment's perceived benefit. From a market perspective, this approval addresses a significant unmet need. CIDP is a debilitating neuromuscular disorder where 85% of patients require ongoing treatment, and nearly 88% experience residual impairment despite current therapies. The flexibility of administration (weekly dosing with potential adjustment to bi-weekly) and delivery formats (vial or prefilled syringe with self-administration options) should enhance patient compliance and convenience. This marks VYVGART SC's second approval in Europe, following its earlier approval for generalized myasthenia gravis (gMG). This expanding indication portfolio strengthens argenx's position in the autoimmune disease market and validates their FcRn inhibitor platform.